Fierce Pharma10d
Lilly's first DTC Ebglyss campaign highlights eczema’s effects on a range of skin tones and age groups
After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...
Yahoo Finance5d
Eli Lilly’s three-year Ebglyss study leaves 50% of AD patients with clear skin
Eli Lilly’s Ebglyss (lebrikizumab-lbkz) has achieved complete skin clearance after three years in 50% of patients with moderate-to-severe atopic dermatitis (AD) in a Phase III trial. The US ...
Eli Lilly posts long-term data for eczema therapy Ebglyss
Eli Lilly (NYSE:LLY) on Friday said that its recently approved eczema therapy Ebglyss led to complete skin clearance in 50% ...
Eli Lilly’s Ebglyss achieved ‘deep and sustained response’ in ADjoin study
New results show Eli Lilly (LLY) and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic ...
Nasdaq8d
Eli Lilly's Ebglyss Monotherapy Injection Shows Sustained Skin Clearance In Atopic Dermatitis
(RTTNews) - Eli Lilly and Co. (LLY) announced that its Ebglyss monotherapy monthly injection demonstrated sustained and deep responses in patients with moderate-to-severe atopic dermatitis over ...
Seeking Alpha8d
Eli Lilly posts long-term data for eczema therapy Ebglyss
Eli Lilly (NYSE:LLY) on Friday said that its recently approved eczema therapy Ebglyss led to complete skin clearance in 50% of individuals who took part in a long-term extension study. Citing data ...